Cancer Immunotherapy Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the cancer immunotherapy market grown in recent years?
The oncology immunotherapy market has seen swift expansion in the recent past. Its growth is predicted to spike from $110.91 billion in 2024 to $125.68 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.3%. Factors such as an increasing incidence of cancer, a shift towards immunotherapy from conventional treatments, burgeoning research and development pursuits for specific disease treatments, enhanced efficacy and precision of the latest therapies, and a growing understanding of the shortcomings of traditional cancer treatment methods have contributed to this growth in the past years.
How is the cancer immunotherapy market size expected to evolve during the forecast period?
It is anticipated that the cancer immunotherapy market will experience significant expansion in the coming years. The market is set to escalate to $194.64 billion by 2029, with a compound annual growth rate (CAGR) of 11.6%. The upswing during this forecast period can be related to the growing approval of innovative immunotherapies for treating cancer, an increased demand for personalized medication, the rise in cancer diagnoses, increased funding in clinical trials for pioneering treatments, and heightened awareness of cancer immunotherapy. The predicted trends for this period include the development of adoptive cell therapies such as car-t cells, the investigation of oncolytic viruses in cancer immunotherapy, the creation of personalized cancer vaccines, the application of artificial intelligence in immunotherapy studies, and a heightened focus on real-world evidence and patient outcomes in treatment choices.
Get your cancer immunotherapy market report here!
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Which key drivers are propelling the cancer immunotherapy market’s growth?
It is anticipated that the cancer immunotherapy market will experience significant expansion in the coming years. The market is set to escalate to $194.64 billion by 2029, with a compound annual growth rate (CAGR) of 11.6%. The upswing during this forecast period can be related to the growing approval of innovative immunotherapies for treating cancer, an increased demand for personalized medication, the rise in cancer diagnoses, increased funding in clinical trials for pioneering treatments, and heightened awareness of cancer immunotherapy. The predicted trends for this period include the development of adoptive cell therapies such as car-t cells, the investigation of oncolytic viruses in cancer immunotherapy, the creation of personalized cancer vaccines, the application of artificial intelligence in immunotherapy studies, and a heightened focus on real-world evidence and patient outcomes in treatment choices.
What are the market segments in the cancer immunotherapy industry?
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp
Which leading companies are shaping the growth of the cancer immunotherapy market?
Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.
What key trends are currently impacting the cancer immunotherapy market’s development?
In the cancer immunotherapy market, a notable trend is the growing adoption of advanced technologies used for cancer immunotherapy. New technologies and diverse therapies aimed at enabling the immune system to detect and combat tumors are appearing at an increasing rate. These include immuno-oncology, cryoablation, bone marrow transplants, and radiation therapy. These technological advances have the potential to bring about marked improvements in cancer treatment outcomes. For example, AstraZeneca plc, a UK-based pharmaceutical and biotechnology firm, reported in October 2022 that it had received approval for Capivasertib in combination with Faslodex, an immunotherapeutic cancer drug developed for treating breast cancer. This treatment has shown its efficacy in tackling recurrence or progression post endocrine therapy in locally advanced or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6768
Which geographic areas are influencing the growth of the cancer immunotherapy market?
North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Lung Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024
Metabolomics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
